Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

Stopped early · Phase 3

Conditions studied: Hyperlipoproteinemia Type III

In brief

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.

Key facts

Study ID

NCT00145431

Run by

Pfizer

People needed

41

Starts

2005-03-01

Expected to finish

2006-12-01

Last updated by the study team

2012-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Familial Dysbetalipoproteinemia (Fredrickson Type III hyperlipoproteinemia)

You may not qualify if…

• Women who are pregnant or lactating, or planning to become pregnant.
• Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
• Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
• Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

Where it is running

• Pfizer Investigational Site — Anaheim, California, United States
• Pfizer Investigational Site — Huntington Beach, California, United States
• Pfizer Investigational Site — Orange, California, United States
• Pfizer Investigational Site — Pacific Palisades, California, United States
• Pfizer Investigational Site — Studio City, California, United States
• Pfizer Investigational Site — Tustin, California, United States
• Pfizer Investigational Site — Hollywood, Florida, United States
• Pfizer Investigational Site — Longwood, Florida, United States
• Pfizer Investigational Site — Tripler Army Medical Center, Hawaii, United States
• Pfizer Investigational Site — Scarborough, Maine, United States
• Pfizer Investigational Site — Portage, Michigan, United States
• Pfizer Investigational Site — Portage, Michigan, United States
• Pfizer Investigational Site — Olive Branch, Mississippi, United States
• Pfizer Investigational Site — Rochester, New York, United States
• Pfizer Investigational Site — Syracuse, New York, United States
• Pfizer Investigational Site — West Seneca, New York, United States
• Pfizer Investigational Site — Sellersville, Pennsylvania, United States
• Pfizer Investigational Site — Greer, South Carolina, United States
• Pfizer Investigational Site — Memphis, Tennessee, United States
• Pfizer Investigational Site — Salt Lake City, Utah, United States
• Pfizer Investigational Site — Seattle, Washington, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States
• Pfizer Investigational Site — London, Ontario, Canada
• Pfizer Investigational Site — Chicoutimi, Quebec, Canada
• Pfizer Investigational Site — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.